Overview of Dr. Cherng
Dr. Hua-Jay Cherng is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 0 years. He is one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He also speaks multiple languages, including Chinese (Mandarin). He has more than 10 publications and over 50 citings.
Office
161 Fort Washington Avenue
Floor G
New York, NY 10032- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
University of Pennsylvania Health SystemInternship, Internal Medicine, 2016 - 2019
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2016 - 2019
Case Western Reserve University School of MedicineClass of 2016
Certifications & Licensure
NY State Medical License 2022 - 2025
TX State Medical License 2019 - 2024
PA State Medical License 2016 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Measurable Residual Disease Monitoring in Lymphoma.Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng> ;Current Hematologic Malignancy Reports. 2023 Dec 1
- 4 citationsPositron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.Cherng, H., Xu, G., Feng, L., Steiner, R., Fayad, L., Strati, P., Nair, R., Nastoupil, L., Lee, H., Neelapu, S., Flowers, C., Rodriguez, M., Wang, M., Hagemeister, F.,...> ;British Journal of Haematology. 2023 Jan 1
- 5 citationsA phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.Hua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, Loretta J Nastoupil, Luis Fayad, Sattva S Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F M Craig, Charle...> ;Blood Advances. 2023 Apr 11
- Join now to see all
Other Languages
- Chinese (Mandarin)
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York- NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
